Study Reveals Metformin May Hinder Exercise Benefits for Diabetics

Recent research indicates that millions of individuals with type 2 diabetes may be undermining their health efforts through the use of the commonly prescribed medication, metformin. A study conducted by researchers at Rutgers University found that metformin inhibits the cardiovascular benefits typically gained from exercise. The findings raise concerns for the over 20 million Americans currently taking this medication while striving to improve their health.

The study involved 72 adults at an elevated risk of metabolic syndrome. Researchers discovered that those taking metformin experienced diminished improvements in blood vessel function, blood sugar regulation, and overall fitness compared to those not on the drug. These results challenge the widely held belief that medication and exercise work synergistically to manage diabetes effectively.

Lead author Steven Malin, a professor in the Department of Kinesiology and Health at Rutgers, expressed concern over the assumptions made by healthcare providers. “Most health care providers assume one plus one equals two,” he said. “The problem is that most evidence shows metformin blunts exercise benefits.”

In this double-blind, placebo-controlled trial, participants were assigned to four groups: high-intensity exercise with a placebo, high-intensity exercise with metformin, low-intensity exercise with a placebo, and low-intensity exercise with metformin. Over a period of 16 weeks, researchers assessed each participant’s blood vessel function and aerobic fitness.

The results were striking. Those in the placebo groups, regardless of exercise intensity, showed a significant improvement in aerobic fitness levels. In contrast, participants taking metformin exhibited no changes in fitness or vascular insulin sensitivity, a critical measure of glucose regulation and cardiovascular health.

The implications of these findings are significant. While regular exercise is known to enhance insulin sensitivity, lower blood glucose levels, and reduce the risk of obesity and heart disease, metformin appears to interfere with these benefits. The study noted that inflammation and fasting glucose levels were worsened in participants taking metformin, further highlighting potential risks associated with the medication.

Malin emphasized the need for healthcare professionals to reevaluate their approach to prescribing metformin alongside exercise. “If you exercise and take metformin and your blood glucose does not go down, that’s a problem,” he stated. The lack of improvement in physical function for those on metformin could pose long-term health risks.

The mechanism behind metformin’s interference remains unclear. Researchers speculate that the drug’s suppression of mitochondrial activity may play a role. By reducing oxidative stress and improving blood sugar regulation, metformin may also inadvertently limit the expected benefits of exercise on mitochondrial function and cardiovascular health.

While the study’s sample size was relatively small, the results underscore the necessity for further investigation into the interaction between metformin and exercise. The researchers stress that the findings do not suggest patients should discontinue metformin or exercise but rather highlight the need for close monitoring of patients who are not achieving the desired health outcomes.

Going forward, Malin advocates for the development of better guidelines for clinicians to help patients effectively manage their diabetes through exercise, even while on medications like metformin. “We need to figure out how to best recommend exercise with metformin,” he said.

The study was published in The Journal of Clinical Endocrinology & Metabolism, contributing valuable insights to the ongoing dialogue about diabetes management and the intersection of medication and lifestyle changes. More research is essential to ensure that individuals with diabetes receive the full benefits of their hard work and therapeutic interventions.